February 01, 2015 7:27 PM ET


Company Overview of Protein Sciences Corporation

Company Overview

Protein Sciences Corporation develops and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, an influenza vaccine; Panblok, a vaccine for pandemic influenza; FluNhance that is used as an additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine, which is used as an antigen for severe acute respiratory syndrome virus. It also provides baculovirus expression vector system for prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applications; GeneXpress, which provides protein production services; expresSF+ cells that optimizes protein production; and research ant...

1000 Research Parkway

Meriden, CT 06450

United States

Founded in 1983





Key Executives for Protein Sciences Corporation

Chief Executive Officer
Chief Technology Officer and Senior Vice President
Chief Administrative Officer
Chief Medical Officer
Head of Government and Clinical Affairs
Compensation as of Fiscal Year 2014.

Protein Sciences Corporation Key Developments

Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation Enter into Agreement to Evaluate Sourcing Flublok® from Japan

Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation announced that they have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu (Japan) Plant of UNIGEN, a subsidiary of UMN Pharma in which IHI holds 50% of the common shares. UNIGEN manufactures Flublok for UMN Pharma at the 21,000L scale - ten times the scale the vaccine is manufactured in the United States. The Gifu plant has two 21,000L bioreactors and has the capacity to add six additional bioreactors. UMN holds a license from Protein Sciences for Flublok for the territories of Japan, China, Korea, Hong Kong, Taiwan and Singapore. UMN is partnered with Astellas to market Flublok in Japan.

Nadine Francis West Joins Protein Sciences Corporation as Vice President, Chief Administration Officer and Corporate Secretary

Protein Sciences Corporation announced that Nadine Francis West of Hartford has been appointed Senior Vice President, Chief Administrative Officer and Corporate Secretary. Prior to joining Protein Sciences, Nadine served as the Vice President and Chief Administrative Officer of the MetroHartford Alliance where she oversaw the Alliance’s $4.9 million budget, served as the Corporate Secretary and led the Finance and Administration Team.

Protein Sciences Corporation Signs License Agreement with Laboratorios Liomont

Protein Sciences Corporation and Laboratorios Liomont S.A. de C.V. (Liomont) have signed a licensing agreement that grants Liomont an license to Flublok (R) (seasonal) and Panblok(R) (pandemic) influenza vaccines for Mexico market and other Latin American countries. Under the terms of the agreement, Liomont will seek regulatory approval for Flublok in Mexico and initially sell Flublok manufactured by Protein Sciences. Liomont has also obtained rights to manufacture Flublok and Panblok in Mexico. Protein Sciences is entitled to significant license and milestone payments and royalties on sales.

Similar Private Companies By Industry

Company Name Region
Charleston Laboratories, Inc. United States
pH Pharmaceutical, Inc. United States
Tego BioSciences Corporation United States
Ash Stevens, Inc. United States
ProlX Pharmaceuticals Corporation United States

Recent Private Companies Transactions

December 19, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protein Sciences Corporation, please visit www.proteinsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.